Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
6.71M
-
Number of holders
-
18
-
Total 13F shares, excl. options
-
402K
-
Shares change
-
+123K
-
Total reported value, excl. options
-
$1.27M
-
Value change
-
+$425K
-
Number of buys
-
9
-
Number of sells
-
-6
-
Price
-
$3.16
Significant Holders of Vivos Therapeutics, Inc. - Common stock, par value $0.0001 per share (VVOS) as of Q2 2025
23 filings reported holding VVOS - Vivos Therapeutics, Inc. - Common stock, par value $0.0001 per share as of Q2 2025.
Vivos Therapeutics, Inc. - Common stock, par value $0.0001 per share (VVOS) has 18 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 402K shares
of 6.71M outstanding shares and own 5.99% of the company stock.
Largest 10 shareholders include UBS Group AG (143K shares), B. Riley Wealth Advisors, Inc. (69.5K shares), GEODE CAPITAL MANAGEMENT, LLC (57.9K shares), VANGUARD GROUP INC (42.6K shares), COMMONWEALTH EQUITY SERVICES, LLC (41K shares), XTX Topco Ltd (20.5K shares), NORTHERN TRUST CORP (12.5K shares), STATE STREET CORP (11.8K shares), MORGAN STANLEY (1.07K shares), and OSAIC HOLDINGS, INC. (793 shares).
This table shows the top 18 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.